A Phase 1/2 Feasibility, Safety, And Activity Study Of PSCA-Specific Chimeric Antigen Receptor Engineered T Cells (BPX-601) In Subjects With Previously Treated Advanced Solid Tumors Read more
A Phase 1/2, Open-Label, Multicenter, Non-Randomized, Safety And Activity Study Of Her-Targeted Dual Switch Car-T Cells (Bpx-603) In Subjects With Previously Treated Advanced Her2-Positive Solid Tumors Read more
Phase 1/2a First-In-Human Study Of BMS-986207 Monoclonal Antibody Alone And In Combination With Nivolumab In Advanced Solid Tumors Read more
Open-Label, Multicenter, Phase 1 Study To Assess The Safety Of P BCMA-101 In Subjects With Relapsed / Refractory Multiple Myeloma (MM) Followed By A Phase 2 Assessment Of Response And Safety (PRIME) Read more
A Multicenter, Open-Label Study With A Randomized Control Arm Of The Efficacy, Safety, And Pharmacokinetics Of Intravenously Infused Berubicin In Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV) After Failure Of Standard First Line Therapy Read more
Prospective Observational Multiple Myeloma Impact Study Prospective Multicenter Study To Measure The Impact Of Mmprofiler On Treatment Intention In Active Multiple Myeloma Patients Read more
A Phase 1/2 Study Of Selinexor In Combination With Standard Of Care (Soc) Therapy For Actively Diagnosed Or Recurrent Glioblastoma Read more
Descartes-11 Consolidation Treatment In Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy Read more
EF-32 (TRIDENT): A Pivotal Randomized, Open-Label Study Of Optune® (Ttfields, 200khz) Concomitant With Radiation Therapy And Temozolomide For The Treatment Of Actively Diagnosed Glioblastoma Read more
